Market Research Logo

Relapsed Multiple Myeloma - Pipeline Review, H2 2015

Relapsed Multiple Myeloma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Relapsed Multiple Myeloma - Pipeline Review, H2 2015’, provides an overview of the Relapsed Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Relapsed Multiple Myeloma Overview
Therapeutics Development
Pipeline Products for Relapsed Multiple Myeloma - Overview
Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis
Relapsed Multiple Myeloma - Therapeutics under Development by Companies
Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes
Relapsed Multiple Myeloma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Relapsed Multiple Myeloma - Products under Development by Companies
Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes
Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development
4SC AG
AB Science SA
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Altor BioScience Corporation
Amgen Inc.
Arno Therapeutics, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Atara Biotherapeutics, Inc.
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cellectar Biosciences, Inc.
Cleave Biosciences
Curis, Inc.
Daiichi Sankyo Company, Limited
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
IGF Oncology, LLC.
Immunomedics, Inc.
Jasco Pharmaceuticals, LLC.
Johnson & Johnson
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Novartis AG
Noxxon Pharma AG
Oncolytics Biotech Inc.
Oncopeptides AB
Onyx Pharmaceuticals, Inc.
Patrys Limited
Pfizer Inc.
Pharma Mar, S.A.
Sanofi
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Threshold Pharmaceuticals, Inc.
Vivolux AB
Relapsed Multiple Myeloma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
4SC-202 - Drug Profile
765IGF-MTX - Drug Profile
ABBV-838 - Drug Profile
acalabrutinib - Drug Profile
ACY-241 - Drug Profile
afuresertib hydrochloride - Drug Profile
alisertib - Drug Profile
alpelisib - Drug Profile
ALT-801 - Drug Profile
ALT-803 - Drug Profile
AMG-224 - Drug Profile
amrubicin hydrochloride - Drug Profile
AR-42 - Drug Profile
AT-7519 - Drug Profile
AT-9283 - Drug Profile
B-701 - Drug Profile
bendamustine hydrochloride - Drug Profile
BI-836909 - Drug Profile
BMS-986016 - Drug Profile
cabozantinib s-malate - Drug Profile
carfilzomib - Drug Profile
CB-5083 - Drug Profile
CB-839 - Drug Profile
CC-90002 - Drug Profile
Cell Therapy to Target WT1 for Cancer - Drug Profile
Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma - Drug Profile
Cellular Immunotherapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile
CUDC-907 - Drug Profile
CWP-291 - Drug Profile
daratumumab - Drug Profile
DKN-01 - Drug Profile
DS-3032 - Drug Profile
elotuzumab - Drug Profile
erismodegib - Drug Profile
evofosfamide - Drug Profile
filanesib - Drug Profile
ganetespib - Drug Profile
GSK-2857916 - Drug Profile
GSK-525762 - Drug Profile
I131-CLR1404 - Drug Profile
ibrutinib - Drug Profile
indatuximab ravtansine - Drug Profile
inebilizumab - Drug Profile
ipilimumab - Drug Profile
isatuximab - Drug Profile
ixazomib citrate - Drug Profile
JP-11646 - Drug Profile
LCL-161 - Drug Profile
lirilumab - Drug Profile
marizomib - Drug Profile
masitinib - Drug Profile
Melflufen - Drug Profile
milatuzumab - Drug Profile
MOR-202 - Drug Profile
MV-NIS - Drug Profile
NL-101 - Drug Profile
olaptesed pegol - Drug Profile
oprozomib - Drug Profile
palbociclib - Drug Profile
PATSM-6 - Drug Profile
pelareorep - Drug Profile
pembrolizumab - Drug Profile
pidilizumab - Drug Profile
PIM-447 - Drug Profile
plerixafor - Drug Profile
plitidepsin - Drug Profile
quisinostat hydrochloride - Drug Profile
Recombinant Protein for Oncology - Drug Profile
ricolinostat - Drug Profile
RRX-001 - Drug Profile
selinexor - Drug Profile
SL-401 - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
ulocuplumab - Drug Profile
urelumab - Drug Profile
vemurafenib - Drug Profile
venetoclax - Drug Profile
VLX-1570 - Drug Profile
vorinostat - Drug Profile
Relapsed Multiple Myeloma - Recent Pipeline Updates
Relapsed Multiple Myeloma - Dormant Projects
Relapsed Multiple Myeloma - Discontinued Products
Relapsed Multiple Myeloma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Relapsed Multiple Myeloma, H2 2015
Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015
Relapsed Multiple Myeloma - Pipeline by 4SC AG, H2 2015
Relapsed Multiple Myeloma - Pipeline by AB Science SA, H2 2015
Relapsed Multiple Myeloma - Pipeline by AbbVie Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2015
Relapsed Multiple Myeloma - Pipeline by Amgen Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Biotest AG, H2 2015
Relapsed Multiple Myeloma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Relapsed Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Relapsed Multiple Myeloma - Pipeline by Calithera Biosciences, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Celgene Corporation, H2 2015
Relapsed Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Cleave Biosciences, H2 2015
Relapsed Multiple Myeloma - Pipeline by Curis, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Relapsed Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Relapsed Multiple Myeloma - Pipeline by GlaxoSmithKline Plc, H2 2015
Relapsed Multiple Myeloma - Pipeline by IGF Oncology, LLC., H2 2015
Relapsed Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
Relapsed Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2015
Relapsed Multiple Myeloma - Pipeline by JW Pharmaceutical Corporation, H2 2015
Relapsed Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by MedImmune, LLC, H2 2015
Relapsed Multiple Myeloma - Pipeline by Medivation, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Merck & Co., Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by MorphoSys AG, H2 2015
Relapsed Multiple Myeloma - Pipeline by Novartis AG, H2 2015
Relapsed Multiple Myeloma - Pipeline by Noxxon Pharma AG, H2 2015
Relapsed Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2015
Relapsed Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Patrys Limited, H2 2015
Relapsed Multiple Myeloma - Pipeline by Pfizer Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2015
Relapsed Multiple Myeloma - Pipeline by Sanofi, H2 2015
Relapsed Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Relapsed Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Relapsed Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Relapsed Multiple Myeloma - Pipeline by Vivolux AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Relapsed Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2015
Relapsed Multiple Myeloma - Dormant Projects, H2 2015
Relapsed Multiple Myeloma - Dormant Projects (Contd..1), H2 2015
Relapsed Multiple Myeloma - Dormant Projects (Contd..2), H2 2015
Relapsed Multiple Myeloma - Dormant Projects (Contd..3), H2 2015
Relapsed Multiple Myeloma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Relapsed Multiple Myeloma, H2 2015
Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report